The latest episode of the DDW ‘In Conversation With’ series is available to listen to below. This week, Bruno Quinney speaks to Anthony Johnson and Matthew Fyfe from Outrun Therapeutics. Outrun is a biotech specialising in protein stabilisation, an approach being applied to treat HPV+ head and… Read More
Alex Bentley, an 1851 Industrial Fellow working with GSK and the University of Strathclyde, discusses how his research into protein degraders will benefit drug discovery efforts across the pharmaceutical industry. First proposed in the early 2000s, targeted protein degradation (TPD) has emerged as a therapeutic modality with the potential… Read More
Galux, a company using AI to drive drug design, has raised $29 million to support its protein therapeutics platform. The Series B financing round brought together existing investors, including InterVest, DAYLI Partners, and PATHWAY Investment, with new investors Yuanta Investment, Korea Development Bank (KDB), SL Investment, NCORE Ventures, SneakPeek Investments, Korea… Read More
DDW’s Megan Thomas attended Nebius’ inaugural AI Discovery Awards in Amsterdam, where top prizes of $100,000 in GPU credits were awarded to four companies pioneering AI breakthroughs in cancer prediction, protein targeting, transcriptomic mapping, and precision diagnostics. The winners were selected from 257 global applications by a panel of 19… Read More
Flow cytometry is a high throughput quantitative analysis tool that employs fluorescent-labelled molecules for multi-parametric analysis of millions of individual cells or particles. In biomedical sciences, the flow cytometry assays involve a careful selection of antibodies, fluorochrome labels for detection, and often requires optimisation of protocols for an accurate analysis… Read More
